- Home
- Automated
- List of product information
- FAMOTIDINE FILM COATED TABLET 40 MG [SIN10209P]
FAMOTIDINE FILM COATED TABLET 40 MG [SIN10209P]
Active ingredients: FAMOTIDINE FILM COATED TABLET 40 MG
Product Info
FAMOTIDINE FILM COATED TABLET 40 MG
[SIN10209P]
Product information
Active Ingredient and Strength | FAMOTIDINE - 40 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | HOVID BHD - MALAYSIA |
Registration Number | SIN10209P |
Licence Holder | GOLDPLUS UNIVERSAL PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | A02BA03 |
INDICATIONS
Famotidine is indicated in the short term treatment of duodenal ulcer, benign gastric ulcer and hypersecretory conditions such as Zollinger-Ellison syndrome. It is also used in the prevention of relapses of duodenal ulceration, symptomatic relief of gastro-oesophageal reflux disease and healing of oesophageal erosions or ulceration associated with gastro-oesophageal reflux disease.
DOSAGE & ADMINISTRATION
Usual adult and adolescent dose:
Duodenal ulcer: Oral, 40 mg once daily at bedtime or 20 mg 2 times daily.
Prophylaxis of recurrent duodenal ulcer: Oral, 20 mg at bedtime.
Gastric ulcer: Oral, 40 mg once daily at bedtime.
Gastric hypersecretory conditions (eg. Zollinger-Ellison syndrome): Oral, 20 mg every 6 hours, the dosage being adjusted as needed and therapy continued for as long as clinically indicated. Doses up to 160 mg every 6 hours have been administered to some patients with severe Zollinger-Ellison syndrome.
Gastro-oesophageal reflux: Oral, 20 mg 2 times daily for up to 6 weeks. The recommended oral dose for oesophagitis due to gastro-oesophageal reflux disease is 20 to 40 mg 2 times daily for up to 12 weeks.
Dosage Adjustment for patients with moderate to severe renal insufficiency: In adult patients with moderate (creatinine clearance < 50 mL/min) or severe (creatinine clearance < 10mL/min) renal insufficiency, the dose of Famotidine may be reduced to half the dose or the dosing interval may be prolonged to 36–48 hours as indicated by patient's clinical response.
Note: The information given here is limited. For further information, please consult your doctor or pharmacist.
CONTRAINDICATIONS
Risk-benefit should be considered when the following medical problems exist:
Cirrhosis
Hepatic and renal function impairment
Sensitivity to any of the histamine H2-receptor antagonists
